Pregled bibliografske jedinice broj: 868145
Theranostic Biomarkers for Schizophrenia
Theranostic Biomarkers for Schizophrenia // International journal of molecular sciences, 18 (2017), 4; 733, 37 doi:10.3390/ijms18040733 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 868145 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Theranostic Biomarkers for Schizophrenia
Autori
Nikolac Perković, Matea ; Nedić Erjavec, Gordana ; Švob Štrac, Dubravka ; Uzun, Suzana ; Kozumplik, Oliver ; Pivac, Nela
Izvornik
International journal of molecular sciences (1422-0067) 18
(2017), 4;
733, 37
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
schizophrenia ; biomarkers ; diagnostic ; prognostic and theranostic biomarkers ; inflammatory ; stress-related ; metabolic ; neurotrophic and neurotransmitter biomarkers
Sažetak
Schizophrenia is a highly heritable, chronic, severe, disabling neurodevelopmental brain disorder with a heterogeneous genetic and neurobiological background, which is still poorly understood. To allow better diagnostic procedures and therapeutic strategies in schizophrenia patients, use of easy accessible biomarkers is suggested. The most frequently used biomarkers in schizophrenia are those associated with the neuroimmune and neuroendocrine system, metabolism, different neurotransmitter systems and neurotrophic factors. However, there are still no validated and reliable biomarkers in clinical use for schizophrenia. This review will address potential biomarkers in schizophrenia. It will discuss biomarkers in schizophrenia and propose the use of specific blood-based panels that will include a set of markers associated with immune processes, metabolic disorders, and neuroendocrine/neurotrophin/neurotransmitter alterations. The combination of different markers, or complex multi-marker panels, might help in the discrimination of patients with different underlying pathologies and in the better classification of the more homogenous groups. Therefore, the development of the diagnostic, prognostic and theranostic biomarkers is an urgent and an unmet need in psychiatry, with the aim of improving diagnosis, therapy monitoring, prediction of treatment outcome and focus on the personal medicine approach in order to improve the quality of life in patients with schizophrenia and decrease health costs worldwide.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
1463002
Ustanove:
Institut "Ruđer Bošković", Zagreb,
Klinika za psihijatriju Vrapče
Profili:
Oliver Kozumplik
(autor)
Suzana Uzun
(autor)
Gordana Nedić Erjavec
(autor)
Dubravka Švob Štrac
(autor)
Nela Pivac
(autor)
Matea Nikolac Perković
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- current contents